TScan Therapeutics, Inc. (TCRX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 10 | 14 | 21 | 3 | 10 | 7 | 4 |
| Operating profit | $m | -136 | -121 | ||||||
| Net profit | $m | -26 | -49 | -66 | -89 | -127 | -130 | -118 | -109 |
| EPS reported | $ | -1.00 | -0.91 | ||||||
| Operating cashflow per share | $ | -1.04 | -0.94 | ||||||
| Capex per share | $ | 0.03 | 0.02 | ||||||
| FCF per share | $ | -1.08 | -0.96 | ||||||
| Free cash flow | $m | -140 | -118 | ||||||
| Net debt | $m | -120 | -67 | ||||||
| Book value equity | $m | 123 | 69 | ||||||
| Book value per share | $ | 0.95 | 0.53 | ||||||
| Number of shares | m | 129.86 | 129.95 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.05 | 1.88 | ||||||
| P/S LTM | x | 12.58 | 18.26 | ||||||
| P/FCF LTM | x | -0.93 | -1.10 | ||||||
| EV/EBITDA LTM | x | -0.58 | -0.64 | ||||||
| EV/Sales LTM | x | 6.93 | 1.30 | ||||||
| Earnings Yield LTM | % | -99.93% | -1.23% | ||||||
| FCF Yield | % | -107.60% | -91.20% | ||||||
| Quality | |||||||||
| ROE | % | -105.40% | -91.94% | ||||||
| ROIC | % | -62.51% | -67.93% | ||||||
| Operating margin | % | -13.15% | -14.09% | ||||||
| Gross margin | % | +72.24% | +92.41% | ||||||
| FCF/Sales | % | -1353.3% | -1367.7% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +266.65% | +152.52% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.48 | -1.30 | ||||||
| Net Debt/EBITDA | x | 0.47 | 0.30 | ||||||
| EBIT/Net interest | x | -49.05 | -46.31 | ||||||
| Net debt/market cap | % | +25.05% | +68.90% | ||||||
| Net debt/Equity | x | -0.97 | -0.98 | ||||||
| Gross debt/equity | x | 0.76 | 1.32 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free